Did you know ? If you order before Friday 14h we deliver 90PCT of the the time next Tuesday, GENTAUR another in time delivery

Pubmed ID :30360692
Publication Date : //

Tamoxifen suppresses paclitaxel-, vincristine-, and bortezomib-induced neuropathy via inhibition of the protein kinase C/extracellular signal-regulated kinase pathway.


Chemotherapy-induced neuropathy is a highly problematic, dose-limiting effect of potentially curative regimens of cancer chemotherapy. When neuropathic pain is severe, patients often either switch to less-effective chemotherapy agents or choose to discontinue chemotherapy entirely. Conventional chemotherapy drugs used to treat lung and breast cancer, multiple myeloma, and lymphoma include paclitaxel, vincristine, and bortezomib. Approximately 68% of patients receiving these anticancer drugs develop neuropathy within the first month of treatment, and while strategies to prevent chemotherapy-induced neuropathy have been investigated, none have yet been proven as effective. Recent reports suggest that chemotherapy-induced neuropathy is associated with signal transduction molecules, including protein kinase C and mitogen-activated protein kinases. It is currently unclear whether protein kinase C inhibition can prevent chemotherapy-induced neuropathy. In this study, we found that tamoxifen, a protein kinase C inhibitor, suppressed paclitaxel-, vincristine-, and bortezomib-induced cold and mechanical allodynia in mice. In addition, chemotherapy drugs induce neuropathy via the protein kinase C/extracellular signal-regulated kinase pathway in the spinal cord in lumbar segments 4-6 and dorsal root ganglions. In addition, tamoxifen was shown to act synergistically with paclitaxel to inhibit tumor-growth in mice injected with tumor cells. Our results indicated that paclitaxel-, vincristine-, and bortezomib-induced neuropathies were associated with the protein kinase C/extracellular signal-regulated kinase pathway in the lumbar spinal cord and dorsal root ganglions, which suggest that protein kinase C inhibitors may be therapeutically effective for the prevention of chemotherapy-induced neuropathy when administered with standard chemotherapy agents.

Authors : Tsubaki Masanobu , Takeda Tomoya , Matsumoto Mikihiro , Kato Natsuki , Yasuhara Shota , Koumoto Yu-Ichi , Imano Motohiro , Satou Takao , Nishida Shozo ,

Related products :

Catalog number Product name Quantity
EIAAB24877 ERK7,ERK-7,ERK8,ERK-8,Extracellular signal-regulated kinase 7,Extracellular signal-regulated kinase 8,Homo sapiens,Human,MAP kinase 15,MAPK 15,MAPK15,Mitogen-activated protein kinase 15
U1357r CLIA Erk1,ERK-1,ERT2,Extracellular signal-regulated kinase 1,Insulin-stimulated MAP2 kinase,MAP kinase 1,MAP kinase 3,MAP kinase isoform p44,MAPK 1,MAPK 3,Mapk3,Microtubule-associated protein 2 kinase 96T
U1357m CLIA Erk1,ERK-1,ERT2,Extracellular signal-regulated kinase 1,Insulin-stimulated MAP2 kinase,MAP kinase 1,MAP kinase 3,MAP kinase isoform p44,MAPK 1,MAPK 3,Mapk3,Microtubule-associated protein 2 kinase 96T
EIAAB24853 Big MAP kinase 1,Bmk1,BMK-1,Erk5,ERK-5,Extracellular signal-regulated kinase 5,MAP kinase 7,MAPK 7,Mapk7,Mitogen-activated protein kinase 7,Mouse,Mus musculus
EIAAB24852 Big MAP kinase 1,Bmk1,BMK-1,Erk5,ERK-5,Extracellular signal-regulated kinase 5,MAP kinase 7,MAPK 7,Mapk7,Mitogen-activated protein kinase 7,Rat,Rattus norvegicus
EIAAB24850 Big MAP kinase 1,BMK1,BMK-1,ERK5,ERK-5,Extracellular signal-regulated kinase 5,Homo sapiens,Human,MAP kinase 7,MAPK 7,MAPK7,Mitogen-activated protein kinase 7,PRKM7
E1357m ELISA kit Erk1,ERK-1,ERT2,Extracellular signal-regulated kinase 1,Insulin-stimulated MAP2 kinase,MAP kinase 1,MAP kinase 3,MAP kinase isoform p44,MAPK 1,MAPK 3,Mapk3,Microtubule-associated protein 2 96T
E1357r ELISA kit Erk1,ERK-1,ERT2,Extracellular signal-regulated kinase 1,Insulin-stimulated MAP2 kinase,MAP kinase 1,MAP kinase 3,MAP kinase isoform p44,MAPK 1,MAPK 3,Mapk3,Microtubule-associated protein 2 96T
E1357r ELISA Erk1,ERK-1,ERT2,Extracellular signal-regulated kinase 1,Insulin-stimulated MAP2 kinase,MAP kinase 1,MAP kinase 3,MAP kinase isoform p44,MAPK 1,MAPK 3,Mapk3,Microtubule-associated protein 2 kinas 96T
E1357m ELISA Erk1,ERK-1,ERT2,Extracellular signal-regulated kinase 1,Insulin-stimulated MAP2 kinase,MAP kinase 1,MAP kinase 3,MAP kinase isoform p44,MAPK 1,MAPK 3,Mapk3,Microtubule-associated protein 2 kinas 96T
15-288-22769 Mitogen-activated protein kinase 7 - EC 2.7.11.24; Extracellular signal-regulated kinase 5; ERK-5; ERK4; BMK1 kinase Polyclonal 0.05 mg
15-288-22770 Mitogen-activated protein kinase 7 - EC 2.7.11.24; Extracellular signal-regulated kinase 5; ERK-5; ERK4; BMK1 kinase Polyclonal 0.05 mg
15-288-22782 Mitogen-activated protein kinase 6 - EC 2.7.11.24; Extracellular signal-regulated kinase 3; ERK-3; MAP kinase isoform p97; p97-MAPK Polyclonal 0.05 mg
15-288-22782 Mitogen-activated protein kinase 6 - EC 2.7.11.24; Extracellular signal-regulated kinase 3; ERK-3; MAP kinase isoform p97; p97-MAPK Polyclonal 0.1 mg
15-288-22770 Mitogen-activated protein kinase 7 - EC 2.7.11.24; Extracellular signal-regulated kinase 5; ERK-5; ERK4; BMK1 kinase Polyclonal 0.1 mg
15-288-22769 Mitogen-activated protein kinase 7 - EC 2.7.11.24; Extracellular signal-regulated kinase 5; ERK-5; ERK4; BMK1 kinase Polyclonal 0.1 mg
EIAAB24878 Erk7,ERK-7,Extracellular signal-regulated kinase 7,MAP kinase 15,MAPK 15,Mapk15,Mitogen-activated protein kinase 15,Rat,Rattus norvegicus
EIAAB24879 Erk7,ERK-7,Extracellular signal-regulated kinase 7,MAP kinase 15,MAPK 15,Mapk15,Mitogen-activated protein kinase 15,Mouse,Mus musculus
EIAAB24843 Erk4,ERK-4,Extracellular signal-regulated kinase 4,MAP kinase 4,MAPK 4,Mapk4,Mitogen-activated protein kinase 4,Mouse,Mus musculus,Prkm4
10-663-45537 ERK2_MAPK1 (p42 MAP Kinase) - Inactive Enzyme Human - EC 2.7.11.24; Extracellular signal-regulated kinase 2; ERK-2; Mitogen-activated protein kinase 2; MAP kinase 2; MAPK 2; p42-MAPK; ERT1 N_A 0.003 mg
10-663-45537 ERK2_MAPK1 (p42 MAP Kinase) - Inactive Enzyme Human - EC 2.7.11.24; Extracellular signal-regulated kinase 2; ERK-2; Mitogen-activated protein kinase 2; MAP kinase 2; MAPK 2; p42-MAPK; ERT1 N_A 0.02 mg
10-663-45536 ERK2_MAPK1 (p42 MAP Kinase) - Active Enzyme Human - EC 2.7.11.24; Extracellular signal-regulated kinase 2; ERK-2; Mitogen-activated protein kinase 2; MAP kinase 2; MAPK 2; p42-MAPK; ERT1 N_A 0.001 mg
10-663-45536 ERK2_MAPK1 (p42 MAP Kinase) - Active Enzyme Human - EC 2.7.11.24; Extracellular signal-regulated kinase 2; ERK-2; Mitogen-activated protein kinase 2; MAP kinase 2; MAPK 2; p42-MAPK; ERT1 N_A 0.005 mg
10-663-45536 ERK2_MAPK1 (p42 MAP Kinase) - Active Enzyme Human - EC 2.7.11.24; Extracellular signal-regulated kinase 2; ERK-2; Mitogen-activated protein kinase 2; MAP kinase 2; MAPK 2; p42-MAPK; ERT1 N_A 0.02 mg
10-663-45537 ERK2_MAPK1 (p42 MAP Kinase) - Inactive Enzyme Human - EC 2.7.11.24; Extracellular signal-regulated kinase 2; ERK-2; Mitogen-activated protein kinase 2; MAP kinase 2; MAPK 2; p42-MAPK; ERT1 N_A 0.01 mg


 

GENTAUR Belgium BVBA BE0473327336
Voortstraat 49, 1910 Kampenhout BELGIUM
Tel 0032 16 58 90 45

Fax 0032 16 50 90 45
info@gentaur.com | Gentaur | Gentaur





GENTAUR Ltd.
Unicorn House, Station Cl
Hertfordshire, Potters Bar EN6 1TL
Whetstone London N20 9BH
Tel 020 3393 8531 Fax 020 8445 9411
uk@gentaur.com | Gentaur | Gentaur

 

 




GENTAUR France SARL
9, rue Lagrange, 75005 Paris
Tel 01 43 25 01 50

Fax 01 43 25 01 60
RCS Paris B 484 237 888

SIRET 48423788800017
RIB 30004 00187 00010092253 10
BNP PARIBAS PARIS PL MAUBERT BIC BNPAFRPPPRG
IBAN FR76 3000 4001 8700 0100 9225 310
france@gentaur.com | Gentaur | Gentaur

GENTAUR GmbH
Marienbongard 20
52062 Aachen Deutschland
Support Karolina Elandt
Tel: +49 0241 40 08 90 86, +49 0241 95 78 94 78, +49 0241 40 08 90 86
Fax: (+49) 241 56 00 47 88

Logistic :0241 40 08 90 86
Bankleitzahl 39050000
IBAN lautet DE8839050000107569353
Handelsregister Aachen HR B 16058
Umsatzsteuer-Identifikationsnummer *** DE 815175831
Steuernummer 201/5961/3925
de@gentaur.com | Gentaur | Gentaur

GENTAUR U.S.A
Genprice Inc, Logistics
547, Yurok Circle
San Jose, CA 95123
CA 95123
Tel (408) 780-0908,
Fax (408) 780-0908,
sales@genprice.com

Genprice Inc, Invoices and accounting
6017 Snell Ave, Ste 357
San Jose, CA 95123




GENTAUR Nederland BV
NL850396268B01 KVK nummer 52327027
Kuiper 1
5521 DG Eersel Nederland
Tel:  0208-080893  Fax: 0497-517897
nl@gentaur.com | Gentaur | Gentaur
IBAN: NL04 RABO 0156 9854 62   SWIFT RABONL2U






GENTAUR Spain
tel:0911876558
spain@gentaur.com | Gentaur | Gentaur






ГЕНТАУЪР БЪЛГАРИЯ
ID # 201 358 931 /BULSTAT
София 1000, ул. "Граф Игнатиев" 53 вх. В, ет. 2
Tel 0035924682280 Fax 0035924808322
e-mail: Sofia@gentaur.com | Gentaur | Gentaur
IBAN: BG11FINV91501014771636
BIC: FINVBGSF

GENTAUR Poland Sp. z o.o.


ul. Grunwaldzka 88/A m.2
81-771 Sopot, Poland
TEL Gdansk 058 710 33 44 FAX  058 710 33 48              

poland@gentaur.com | Gentaur | Gentaur

Other countries

Österreich +43720880899

Canada Montreal +15149077481

Ceská republika Praha +420246019719

Danmark +4569918806

Finland Helsset +358942419041

Magyarország Budapest +3619980547

Ireland Dublin+35316526556

Luxembourg+35220880274

Norge Oslo+4721031366

Sverige Stockholm+46852503438

Schweiz Züri+41435006251

US New York+17185132983

GENTAUR Italy
SRL IVA IT03841300167
Piazza Giacomo Matteotti, 6
24122 Bergamo Tel 02 36 00 65 93
Fax 02 36 00 65 94
italia@gentaur.com | Gentaur | Gentaur